Drawing for FERIFER

USPTO serial 79122733

FERIFER

Reviewed by CopyMark Law Group

Reg. 4441884Status 404
Filing date
Status date
Registration date
Dec 3, 2013
Examiner
FINNEGAN, TIMOTHY
Law office
POST REGISTRATION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with FERIFER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John S. Egbert

John S. Egbert Egbert, McDaniel & Swartz, PLLC1001 Texas Ave., Suite 1250Houston, TX 77002UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
003[ Perfumery, cosmetics, deodorants for personal use; soaps for personal use ]SECTION 71 - CANCELLED—
005Pharmaceuticals for human health in the treatment of anemia and assisting energy metabolism; systemic anti-infectives, namely, antibacterial and antifungal pharmaceuticals; musculo-skeletal system pharmaceutical products for the treatment of musculo-skeletal system diseases; cardiovascular pharmaceuticals, namely, diuretics, lipid lowering agents, beta blocking agents, calcium antagonists and other cardiovascular products; pharmaceuticals for the prevention and treatment of disorders of the nervous system, namely, analgesics, psychoanaleptics, psycoleptics, anti-epileptics, central nervous system drugs, anaesthetics, anti-Parkinson preparations; pharmaceuticals for the treatment of respiratory diseases and asthma; dermatological pharmaceutical products; pharmaceuticals for the treatment of hormonal disorders and the prevention of osteoporosis; anti-diabetic pharmaceuticals; pharmaceuticals for the treatment of bone diseases and joint diseases; pharmaceuticals for the treatment of viral and infectious diseases; pharmaceuticals for use as antineoplastic agents; pharmaceuticals for the treatment of immune system related diseases and disorders; pharmaceuticals for the treatment of kidney diseases; pharmaceuticals for ophthalmological use; chemical preparations for medical purposes, namely, vitamins and mineral supplements to support the growth of children, vitamins and dietary supplements to support arousing the appetiteSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 4, 2023DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Apr 4, 2023DETHDEATH OF INTERNATIONAL REGISTRATION—
Dec 3, 2022REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Jan 22, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 3, 2020INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
May 7, 2020XXSSGENERIC MADRID TRANSACTION SENT TO IB—
May 7, 2020XXCRGENERIC MADRID TRANSACTION CREATED—
Feb 13, 2020INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jun 13, 2019NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Jun 13, 2019NA15SEC. 15 ACKNOWLEDGEMENT - E-MAILED—
Jun 13, 201915AKREGISTERED - SEC. 15 ACKNOWLEDGED—
Jun 13, 201971.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
May 30, 2019APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 17, 201971AFREGISTERED-SEC.71 FILED—
May 17, 2019ES75TEAS SECTION 71 & 15 RECEIVED—
Dec 3, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Mar 15, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 3, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 8, 2016NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 16, 2015NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 28, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 7, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 7, 2014FIMPFINAL DISPOSITION PROCESSED—
Mar 3, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 3, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 17, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 17, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 16, 2013GPNXNOTIFICATION PROCESSED BY IB—
Sep 5, 2013ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Aug 28, 2013OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 28, 2013OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Aug 28, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 13, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 12, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 24, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 24, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 18, 2013ALIEASSIGNED TO LIE—
Jul 11, 2013ALIEASSIGNED TO LIE—
Jul 9, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 8, 2013RFNTREFUSAL PROCESSED BY IB—
Jan 15, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 15, 2013RFRRREFUSAL PROCESSED BY MPU—
Jan 11, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 10, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 9, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 7, 2013DOCKASSIGNED TO EXAMINER—
Jan 7, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 3, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance